Full View

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - Blood, 2007 - ashpublications.org
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is
a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR …
被引用次数：128 相关文章
[HTML] sciencedirect.com

[HTML][HTML] Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - Blood, 2007 - Elsevier
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is
a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR …

[引用][C] Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL (+) leukemias

E Weisberg, L Catley, RD Wright, D Moreno… - …, 2007 - espace.library.uq.edu.au
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is
a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR …

[引用][C] Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

E WEISBERG, L CATLEY, E HALL-MEYERS… - Blood, 2007 - pascal-francis.inist.fr
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+
leukemias CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

E Weisberg, L Catley, RD Wright, D Moreno… - …, 2007 - pubmed.ncbi.nlm.nih.gov
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is
a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR …
[HTML] nih.gov

[HTML][HTML] Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias

E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - Blood, 2007 - ncbi.nlm.nih.gov
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is
a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR …

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - Blood, 2006 - europepmc.org
Drug resistance resulting from emergence of imatinib-resistant BCR-ABL point mutations is
a significant problem in advanced-stage chronic myelogenous leukemia (CML). The BCR …
[PDF] researchgate.net

[PDF][PDF] Beneficial Effects of Combining Nilotinib and Imatinib in Preclinical Models of BCR/ABL+ Leukemias

E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - researchgate.net
Drug resistance resulting from emergence of imatinib-resistant Bcr-Abl point mutations is a
significant problem in advanced stage chronic myelogenous leukemia (CML). The Bcr-Abl …
[PDF] academia.edu

[PDF][PDF] Beneficial Effects of Combining Nilotinib and Imatinib in Preclinical Models of BCR/ABL+ Leukemias

E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - academia.edu
Drug resistance resulting from emergence of imatinib-resistant Bcr-Abl point mutations is a
significant problem in advanced stage chronic myelogenous leukemia (CML). The Bcr-Abl …

[引用][C] Beneficial effects of combining nilotinib and imatinib in preclinical models of Bcr-Abl^+ leukemias

E WEISBERG - Blood, 2007 - cir.nii.ac.jp